个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Yuan, Y.[1] ; Deng, Y.[2] ; Jin, Y.[3] ; Pan, Y.[4] ; Wang, C.[5] ; Wang, Z.[6] ; Zhang, Z.[7] ; Meng, X.[8] ; Hu, Y.[9] ; Zhao, M.[10] ; Wang, H.[11] ; Yang, N.[12] ; Wu, D.[13] ; Dong, X.[14] ; Huang, D.[15] ; Sun, M.[16] ; Liu, L.[17] ; Hua, D.[18] ; Guo, Z.[19,20] ; Ding, K.[21] ;
机构： [1]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China [2]Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China [3]Sichuan Canc Hosp, Dept Med Oncol, Chengdu, Peoples R China [4]Anhui Prov Hosp, Dept Tumor Chemotherapy, Hefei, Peoples R China [5]Hunan Tradit Chinese Med Coll, Affiliated Hosp 1, Dept Oncol, Zhuzhou, Peoples R China [6]Tangshan Peoples Hosp, Dept Radiochem 2, Tangshan, Peoples R China [7]Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China [8]Shandong Prov Canc Hosp, Thorac Radiat Oncol Ward 4, Jinan, Peoples R China [9]Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China [10]China Med Univ, Affiliated Hosp 1, Med Oncol Dept, Shenyang, Peoples R China [11]Henan Canc Hosp, Resp Dept, Zhengzhou, Peoples R China [12]Hunan Canc Hosp, Lung & Gastrointestinal Oncol Dept, Changsha, Peoples R China [13]Hubei Canc Hosp, Hepatopancreatobiliary Surg Dept, Wuhan, Peoples R China [14]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Thorac Oncol, Wuhan, Peoples R China [15]Tianjin Med Univ, Dept Pulm Oncol, Canc Inst & Hosp, Tianjin, Peoples R China [16]Shandong First Med Univ, Cent Hosp, Dept Med Oncol, Jinan, Peoples R China [17]Shandong Univ, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China [18]Wuxi Peoples Hosp, Dept Oncol, Wuxi, Jiangsu, Peoples R China [19]Fujian Canc Hosp, Dept Special Demand Ward, Fuzhou, Peoples R China [20]Fujian Canc Hosp, Dept Clin Nutr, Fuzhou, Peoples R China [21]Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.241
ISSN：
基金：
Innovent Biologics, Inc.; Suzhou, Jiangsu, China
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
推荐引用方式(GB/T 7714)：
Yuan Y.,Deng Y.,Jin Y.,et al.Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies[J].ANNALS OF ONCOLOGY.2023,34:S1512-S1512.doi:10.1016/j.annonc.2023.10.241.
APA：
Yuan, Y.,Deng, Y.,Jin, Y.,Pan, Y.,Wang, C....&Ding, K..(2023).Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies.ANNALS OF ONCOLOGY,34,
MLA：
Yuan, Y.,et al."Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies".ANNALS OF ONCOLOGY 34.(2023):S1512-S1512

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号